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Abstract. The transplantation of organs, cells, and tissues has burgeoned 
during the last quarter century, with the development of multiple new 
specialty fields. However, the basic principles that made this possible 
were established over a three-decade period, beginning during World War 
II and ending in 1974. At the historical consensus conference held at 
UCLA in March 1999, 11 early workers in the basic science or clinical 
practice of transplantation (or both) reacbed agreement on tbe most 
significant contrihutions of tbis era tbat ultimately made transplantation 
the robust clinical disc;ipline it is today. These discoveries and achieve-
ments are summarized here in six tables and annotated witb references. 
The symposium making up this issue of the Journal was held at the 
University of California, Los Angeles (UCLA) and announced by 
the Department of Surgery hosts as "a unique and historic meet-
ing at which pioneers of transplantation from around the world 
will present and discuss landmarks in the advancement of trans-
plantation biology." The participants (in alphabetical order) were: 
Leslie B. Brent (London), Roy Y. Caine (Cambridge, UK), Jean 
Dausset (Paris), Robert A. Good (St. Petersburg, FL), Joseph E. 
Murray (Boston), Norman E. Shumway (Palo Alto), Robert S. 
Schwartz (Boston), Thomas E. Starzl (Pittsburgh), Paul I. Ter-
asaki (Los Angeles), E. Donnall Thomas (Seattle), Jon J. van 
Rood (Leiden). 
Each of these 11 pioneers provided for publication their reflec-
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tions about their own unique contributions. The ultimate objec-
tive, however, was to reach a consensus by the group on what were 
the most critical historical discoveries that made transplantation a 
form of clinical therapy. Carl G. Groth (Stockholm) was invited to 
be the Chairman for these consensus deliberations and to prepare 
the executive summary. 
Historical landmark status was restricted to contributions made 
at least a quarter of a century ago.· By this time it had been 
established that rejection of organ allografts could be prevented 
or reversed with immunosuppressive drugs and that variable do-
nor-specific immunologic tolerance of the graft subsequently de-
veloped in many patients. Long-term survival of human recipients 
of organ and bone marrow allografts had been repeatedly ob-
tained, ensuring continuation of such clinical efforts. A large 
number of HLA antigens had been discovered, allowing efforts at 
tissue matching to proceed. The scientific articles annotating this 
progress are listed in six tables under the following headings: 
transplantation immunology, bone marrow transplantation, renal 
transplantation, liver transplantation, heart transplantation, and 
tissue matching. The material presented in these tables, including 
the citations, originated from the participants of the symposium. 
It should be noted that transplantation could not have pro-
ceeded without contemporaneous advances in general and tho-
racic surgery, medicine, and anesthesia, such ;:tS open-heart sur-
gery, renal dialysis, antibiotics, and intensive care technology. The 
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Table 1. Transplantation immunology. 
Author Discovery or application Year published Reference 
Gibson Defined the immunologic nature of skin allograft rejection in humans, 
confirmed subsequently with controlled rabbit experiments. 
1943 
Owen Discovered that bovine dizygotic twins with placental vascular anastomoses 
(freemartin cattle) were red blood cell chimeras. 
1945 2 
Burnet Based on Owen's observations and on studies of lymphocytic 
choriomeningitis virus by Traub, Burnet, and Fenner postulated "the 
development of tolerance ... during embryonic life." 
1949 
Anderson Demonstrated mutual tolerance to skin grafts by freemartin cattle twins and 
speculated that "actively acquired tolerance" was responsible. 
1951 4 
Billingham Produced actively acquired donor specific tolerance to skin allografts in mice 
injected during late fetal life with donor hematolymphopoietic cells. 
1953 5 
Simonsen 
Billingham 
Independently demonstrated GVHD in chick embryos (manifested as 
pancytopenia) and mice (runt disease) after intravenous injection of adult 
spleen cells. 
1957 
1957 
Starzl Reported evidence that human kidney allografts under azathioprine-
prednisone induced variable donor specific nonreactivity. 
1963 
GVHD: graft-versus-host disease. 
cardiopulmonary resuscitation procedures introduced during the 
1950s were particularly influential because they mandated redef-
inition of death in terms of irreversible brain damage rather than 
the cessation of heartbeat and respiration. While salvaging count-
less victims of cardiac or pulmonary arrest, the new methods also 
resulted in brain-dead corpses on physiologic life support. 
In 1966, at a symposium on medical ethics in London, G.P.I. 
Alexandre described the criteria of brain death that had been used 
in Belgium and France for discontinuing mechanical ventilation of 
"heart-beating cadavers." It became possible thereby to remove 
kidneys and other organs from cadaver donors with an intact 
circulation. The concept was further eI3.borated in a Harvard-
based ad hoc committee report in 1968 in the Journal of the 
American Medical Association. The impact on transplantation of 
cadaver organs was immediate and lasting. 
Transplantation Immunology 
The modern age of transplantation immunology (Table 1) [1-8] 
began·with three seminal observations. First, rejection is a host-
versus-graft (HVG) immune reaction. Second, a similar immune 
reaction [graft -versus-host (GVH) 1 may occur in reverse and lead 
to lethal graft-versus-host disease (GVHD). Third, it is possible 
under well defined experimental conditions to avert rejection as 
well as GVHD and to induce tolerance of alloantigens, which is 
strongly associated with the persistence in the recipient of donor 
leukocyte chimerism. 
The next step was the recognition that organ allografts are 
inherently tolerogenic, a property without which their transplan-
tation with long survival in the recipient would not be possible 
(Table 1). The tolerance induced by organs usually is manifested 
only under an umbrella of immunosuppression, but it is not a 
prerequisite in some animal models, particularly if the allograft is 
the leukocyte-rich liver (see also Table 4). 
The discoveries listed in Table 1 were made piecemeal over a 
period of 25 years, obscuring the fact that all three of the funda-
mental phenomena studied by early workers (i.e., HVG, GVR, 
and acquired tolerance) were involved, but to different degrees, in 
the "acceptance" of organ allografts and the tolerance induced by 
allogeneic bone marrow following recipient cytoablation. In 1992 
the mechanistic linkage of engraftment after these two kinds of 
transplantation was established with the discovery of donor leu-
kocyte micro chimerism in long-surviving human organ recipients. 
The clonal selection theory proposed in 1949 by Burnet and 
Fenner marked the beginning of a new wave in immunology, from 
which transplantation is often viewed as a mere stream. Instead, 
transplantation is a mighty tributary. It fostered research into the 
mechanisms of the destructive antigraft immune response and the 
control of this response. From these efforts, directly or indirectly, 
came the discovery of the function of the lymphocyte (1959-1961) 
and the role of the thymus in the ontogeny of the immune system 
(1961); delineation (1958-1963) of the human major histocom-
patibility complex (MHC); distinction of the T and B lymphocyte 
subsets (1967-1968); and mainly by study of antiviral immune 
responses, demonstration of the MHC-restricted nature of the 
adaptive immune response (1968-1974). 
Bone Marrow Transplantation 
Bone marrow transplantation (Table 2) [9-22J had its roots in 
radiobiology and hematology, and it was influenced by clinical 
studies of certain inherited immune deficiency diseases. Early in 
these efforts it was learned that engraftment of histoincompatible 
bone marrow can cause lethal GVHD in a recipient rendered 
immunologically defenseless by cytoablation, a complication also 
predicted in recipients with immune deficiency disease. Conse-
quently, the preclinical and clinical development of bone marrow 
transplantation was delayed until reliable methods of HLA typing 
and matching became available. 
The first completely successful bone marrow transplantations 
were in children with immune deficiency diseases whose family 
donors were selected with relatively primitive first-generation tis-
sue-matching techniques. Because of their T cell deficiency, these 
recipients did not require the cytoablation and postgrafting im-
munosuppression needed with other indications for bone marrow 
transplantation. With the use of methotrexate as an immunosup-
pressant in cytoablated recipients, bone marrow transplantation 
subsequently was applied with steadily improving results in those 
with an array of benign and malignant hematolymphopoietic dis-
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Table 2. Bone marrow transplantation. 
Author 
Jacobson 
Lorenz 
Main 
Ford 
Barnes 
Thomas 
Thomas 
Thomas 
Mathe 
Storb 
Gatti" 
Bach" 
deKoning" 
Thomas 
Discovery or application 
Protection against lethal irradiation by spleen shielding, mistakenly ascribed 
to humoral factors. 
Protection against lethal irradiation by injection of bone marrow, mistakenly 
ascribed to humoral factors. 
Protection against lethal irradiation in mouse by infusion of bone marrow 
cells and subsequent acceptance of skin allograft from the marrow donor 
(tolerance). Recognized analogy to neonatal tolerance. 
Proved with cytogenetic techniques that marrow cells of mouse reconstituted 
with bone marrow after lethal total body irradiation (TBl) were donor 
origin. 
First attempt to treat leukemia in mice by bone marrow transplantation 
after lethal TBI. 
First attempts to treat malignancy in human patients by high dose 
chemotherapy or TBI and an infusion of marrow, showing safety of the 
infusion and one example of transient engraftment. 
Two children with leukemia given twice the lethal dose of TBI and bone 
marrow from an identical twin had benign hematologic recovery. 
Recurrence of leukemia led to the subsequent addition of chemotherapy 
to TBL 
First outbred animals (dogs) to he successfully engrafted with allogeneic 
marrow; conditioning with TBI and treatment after grafting with a short 
course of methotrexate. Graft rejection, other causes of graft failure, and 
GVHD described. 
World's first prolonged engraftment of human allogeneic bone marrow; 
adult recipient with leukemia conditioned with TBI. Died without disease 
recurrence after 20 months, probably from complications of GVHD. 
After developing dog typing sera, achieved survival of most 
histocompatibility matched, but not of unmatched, recipients of bone 
marrow from littermate donors. Recipients cytoablated and treated with a 
short course of postgraft methotrexate. 
After initial illuminating analyses of the inborn errors of lymphocyte 
development [X-linked agammaglobulinemia, thymic alymphoplasia, and 
severe combined immunodeficiency disease (SCID)] as experiments of 
nature, Good suggested a new two-component concept of immunity and 
performed the world's first completely successful bone marrow transplant 
in a child with otherwise uniformly lethal X-SCID. A second marrow 
transplant from the same donor cured a complicating aplastic anemia in 
this patient, also for the first time. 
This was followed by a partially successful allogeneic bone marrow 
engraftment in a child with Wiskott-Aldrich syndrome. 
Successful allogeneic bone marrow plus thymus engraftment was done 
subsequently in a child with lymphopenic immune deficiency. 
Review of bone marrow transplantation, induding description of first large 
series of patients with aplastic anemia or leukemia given allogeneic 
marrow grafts from matched siblings. Problems with GVHD and 
opportunistic infections defined, with emphasis on the importance of 
histocompatibility, and discussion of possible use of matched unrelated 
donors. 
"These three patients did not need myeloablation or postgraft immunosuppression. 
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Year published Reference 
1951 9 
1951 to 
1955 11 
1956 12 
1957 13 
1957 14 
1959 15 
1962 16 
1963 17 
1968 18 
1968 19 
1968 20 
1969 21 
1975 22 
eases, other kinds of malignancies, and numerous inborn errors of 
metabolism. 
Kidney Transplantation 
Three factors made the kidney a pathfinder organ in transplanta-
tion (Table 3) [8,23-47]. One was the development of dialysis for 
the treatment of acute, and ultimately chronic, renal failure. The 
second was the fact that the kidney is a paired organ, ensuring a 
supply of surgicaJly removed "free kidneys" and, increasingly after 
1953, physiologically ideal live donor kidneys. Third, its technical 
simplicity and the ease with which allograft function could be 
monitored made kidney transplantation ideal for laboratory and 
clinical investigation. 
By 1974 kidney transplantation had already gone through the 
four eras shown in Table 3 defined by: no immunosuppression, 
immunosuppression with total body irradiation (TBl), the first use 
of drugs to prevent rejection (azathioprine) or reverse it (pred-
nisone), and the introduction of adjunct anti-lymphocyte antibody 
therapy. Each major improvement in immunosuppression up to 
1974 and subsequently permitted goals in kidney transplantation 
to be reached that were not attainable before. 
Thus the transition from no therapy to TBI corresponded with 
the step from identical to fraternal twin transplantation. The 
change to azathioprine-based treatment established kidney trans-
plantation as a clinical service from 1963 onward, especiaJly using 
kidneys from living related donors. Cadaver kidney transplanta-
tion burgeoned with the acceptance of brain death during the late 
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Table 3. Kidney transplantation during four eras. 
Author 
Preimmunosuppression 
Carrel 
Lawler 
Kiiss 
Michon 
Hume 
Murray 
Merrill 
Total body irradiation 
Murray 
Merrill 
Hamburger 
Hamburger 
Kiiss 
Cheqlical immunosuppression 
Schwartz 
Schwartz 
Meeker 
Caine 
Zukoski 
Caine 
Murray 
Murray 
Starzl 
Starzl 
Antibody immunosuppression 
Waksman 
Woodruff 
Monaco 
Starzl 
Discovery or application 
Developed vascular anastomotic techniques used for organ 
transplantatIOn today. 
Surgically excised ("free") kidney allograft transplanted to 
recipient nephrectomy site. Function controversial. 
Free kidneys or kidney, from guillotined donors transplanted 
with surgical teChniques still used today. 
First use of living related donor kidney (mother to son): good 
function before rejection at 3 weeks. 
Nine cadaveric or free kidneys transplanted, eight to thigh and 
one to an orthotopic location. One thigh kidney functioned 
for 5 months. 
First 'transplantation of identical twin kidney on 12/23/54, 
reported first in abstract [28] and more completely the 
following year [29]. Later report of first nine cases included 
description of tirst posttransplant pregnancy. 
Renal allograft from fraternal twin transplanted (1/24/59) to a 
recipient preconditioned with sublethal TBl [30] more fully 
reported elsewhere [31]. This was the first long survival of an 
organ allograft, an objective not previously achieved in an 
animal model. 
Second successful fraternal twin kidney transplantation using 
TBI, perfonned June 1959. 
Successful transplantations of two living related but non twin 
kidney allografts using TBI; secondary steroid administration 
mentioned. 
Eighteen-month survival of two nonrelated kidney allografts 
using TBl; secondary steroid and 6-mercaptopurine (6-MP) 
administration noted, without details. 
Showed in rabbits given bovine serum albumin (BSA) while 
also being treated with 6-MP that the 6-MP suppressed the 
antibody response to BSA and rendered the animals tolerant 
of the foreign protein. The experiments were driven by the 
hypothesis that the proliferating immunocytes of an 
expanding antigen-specific clone would be selectively 
vulnerable to antimetabolite drug therapy. 
Independently demonstrated a ti-MP dose-related prolongation 
of rabbit skin allograft survival. 
Moved from the skin to an organ allograft model and 
demonstrated (independent from each other) prolongation 
by 6-MP of canine kidney allograft survival. 
Further extensive preclinical studies (in Murray's Boston 
laboratory) of a report on efficacy in dogs of 6-MP and its 
analogue azathioprine. 
Clinical trials begun with 6-MP and azathioprine. 
Report of first 13 patients treated with 6-MP or azathioprine, 
one of whom reached 1 year with a still functioning but 
failing kidney allograft on 4/5/63. . 
First systematic use of azathioprine and prednisone with long 
survival of most of kidney allografts. 
Clinical experience summarized with azathioprine/prednisone 
therapy in recipients of 67 kidney allografts and 6 baboon 
xenografts. 
Demonstration of anti-lymphocyte serum (ALS) efficacy with 
skin allograft test model in rats. 
Showed additive protection of skin allografts in rats using ALS 
combined with tllOracic duct drainage. 
Convincing demonstration of the therapeutic value of ALS in 
the canine kidney transplant model. 
First climcal trial of anti-lymphocyte globulin (ALG) as an 
adjunct to azathioprine and prednisone for human kidney 
transplantation. With the hybridoma technology of Kohler 
and Milstein (1975) monoclonal antibodies could be raised 
against discrete immunologic targets. In 1981 anti-CD3 
antibody (OKT3) lVas introduced clinically. 
Year published 
1902 
1950 
1951 
1953 
1955 
1955 
1956 
1960 
1959 
1962 
1962 
1959 
1960 
1959 
1960 
1960 
1961 
1962 
1963 
1963 
1964 
1961 
1963 
1966 
1967 
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Reference 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
8 
43 
44 
45 
46 
47 
-·--"----_______ ft __ • 
838 
Table 4. Liver transplantation. 
Author 
Preimmunosuppression 
Weich 
Moore 
Starzl 
Starzl 
Immunosuppression era 
Starzl 
Starzl 
Starzl 
Cordier 
Starzl 
CaIne 
CaIne 
Starzl 
Starzl 
Discovery or application 
First mention of hepatic transplantation in the literature, with insertion 
of an auxiliary liver in unmodified dogs. 
Independent studies in Boston and Chicago of liver replacement 
(orthotopic transplantation) in unmodified dogs. 
Transplantation in dogs of multiple abdominal viscera, including liver 
and intestine, nearly identical to human procedures done three 
decades later. 
World's first three attempts at orthotopic liver transplantation in 
humans (March 1, May 5, and June 24, 1963) with maximum survival 
of 21 days. 
Discovery that splanchnic venous blood of dogs contained 
hepatotrophic factor(s), the most important of which was later 
proved to be insulin; the finding dictated methods of liver allograft 
revascularization. 
First> I-year survival after liver replacement in any species (here 
mongrel dogs) with recognition of the liver's unusual ability to 
induce tolerance under a 3- to 4-month course of azathioprine, or in 
this canine model after only a few perioperative injections of ALS or 
ALG [47J. 
Observed that liver allografts in untreated pigs frequently were not 
rejected. This finding of spontaneous tolerance to livers was 
promptly confirmed by Peacock and Terblanche in Bristol and by 
Caine in Cambridge. 
First report of prolonged survival of four (of seven) children after 
orthotopic liver transplantation between July 1967 and March 1968. 
Report of first four patients in the Cambridge (England) liver 
replacement series. including an adult with >4 months survival. 
Showed that spontaneous tolerant pig liver recipients also were 
tolerant to skin and kidney allografts from the same donor. 
Text summarizing experience at the University of Colorado with 25 
liver replacements to March 1969 and 8 cases elsewhere. 
Metabolic abnormality of Wilson's disease corrected, first of more than 
two dozen liver-based inborn errors cured or ameliorated with liver 
replacement. These liver recipients and patients cured of mesoderm-
based inborn errors by bone marrow transplantation were the first 
examples of effective genetic engineering. 
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Year published Reference 
1955 48 
1960 49 
1960 50 
1960 51 
1963 52 
1964 53 
1965 54 
1966 55 
1968 56 
1968 57 
1969 58 
1969 59 
1971 60 
1960s and the subsequent establishment of organ procurement 
agencies, usually associated with clinical immunology laboratories 
for tissue (HLA) matching. By 1974 renal transplantation had 
become a government-financed component of health care in most 
Western countries. 
bles 1, 4) is that most of these patients have been able to 
discontinue immunosuppressive therapy without rejecting their 
grafts. 
The ripple effects of liver transplantation included discovery of 
the first hepatotrophic factors (beginning with insulin) that are 
involved in hepatic growth control and regeneration. More than 
two dozen liver-based inborn errors of metabolism have been 
corrected by liver transplantation, with clarification of disease 
mechanisms in some. 
Liver Transplantation 
After a failed trial in 1963, liver transplantation was successfully 
performed in humans in July 1967 (Table 4) (48-60]. Hepatic 
replacement was initially viewed as too difficult to be technically 
feasible, particularly in terminally ill patients for whom artificial 
organ support comparable to renal dialysis was not available. 
Instead, challenges generated by its surgical difficulty and physi-
ologic complexity made liver transplantation the co-leader after 
1963 (with the kidney) or the leader in the development of broadly 
applicable advances of surgical technique, immunosuppression, 
and means of multiple organ procurement and preservation. 
Despite a high mortality rate during the first year after liver 
transplantation, nearly two dozen recipients from this early era 
have been stable for 20 to more than 29 years using immunosup-
pression with azathioprine. prednisone, and antilymphocyte glob-
ulin (ALG). The proof of the liver's unusual tolerogenicity (Ta-
Heart Transplantation 
The landmarks of heart transplantation are summarized in Table 
5 (61-69J. Studies of heart transplantation were carried out at 
Stanford University in dogs and subhuman primates from the late 
1950s to 1967. The results justified the decision by this group to 
proceed clinically, as announced by interview in the November 20, 
1967, issue of the Journal of the American Medical Association. On 
December 3, heart replacement was carried out in Cape Town 
following an extended visit by the South African team leader to 
Stanford and other American transplant centers. The first South 
African recipient died from infection after 18 days, but the second 
patient (January 2, 1968) lived several years. On January 5, 1968, 
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Table 5. Heart transplantation. 
Author Discovery or application Year published Reference 
Cass Described standard current practice of combining the multiple pulmonary 
venous and venacaval anastomoses into two large atrial anastomoses. 
No dogs survived the operation. 
1959 61 
Lower Independently developed same procedure as Cass/Brock, preserving 
allografts with immersion hypothermia. Dogs recovered. 
1960 62 
Lower Technically successful canine heart-lung transplantation in 
nonimmunosuppressed dogs with 5-day survival. With long survival the 
same operation was done under cyclosporine two decades later. first in 
monkeys and then in humans. 
1961 63 
Lower Immersion hypothermia of canine allografts at 2°_4°C adequately 
preserved dog hearts for 7 hours. 
1962 64 
Dong Demonstrated normal heart function and rei nervation of cardiac 
autografts 2 years after transplantation in dogs. 
1964 65 
Hardy Transplantation of chimpanzee heart to human recipient. The heart was 
too small to support the circulation and failed after 2 hours. 
1964 66 
Lower First long survival (up to 9 months) of heart allografts in any species 
(here dogs). Azathioprine-based immunosuppression was guided by 
electrocardiogram (ECG) voltage changes, espeCially R-wave 
diminution. 
1965 67 
Barnard Description of the world's first transplantation of a human heart in Cape 
Town on 12/3/67, with 18 days survival. A second attempt in New York 
on 12/6/67 failed after 6 hours. A third recipient, operated in Cape 
Town on 1/2/68, survived for several years. 
1967 68 
Stinson The world's fourth human heart transplantation at Stanford on 1/5/68 was 
successful and inaugurated the long-standing thoracic organ transplant 
program at that institution. 
1970 69 
the Stanford program recorded its inaugural human case, which 
was successfuL 
Graft survival after heart transplantation using triple-drug im-
munosuppression (azathioprine, prednisone, ALG) was essen-
tially equivalent to that of cadaver kidney transplantation. As with 
kidney and liver transplantation, many of the pioneer cardiac 
recipients enjoyed an excellent quality of life, ensuring prompt 
acceptance and widespread application of all these operations 
when better immunosuppression became available. 
Tissue Matching 
The ABO blood groups, the compatibility of which was later 
found to be a requirement for transfusion and for bone marrow 
and organ transplantation, were discovered in 1901 [70]. Similarly, 
it was necessary to develop methods to type human tissue antigens 
and then to determine which were compatible or incompatible 
'with those of the donor (Table 6) [70-94]. This was made possible 
with the discovery in transfused patients, and in women who had 
been pregnant, of leukoagglutinating and lymphocytotoxic anti-
bodies that recognized alloantigens. 
The introduction of computer-assisted search systems allowed 
delineation of families of antibodies that reacted with individual 
alloantigens and also made feasible the grouping of alloantigens 
into the two closely associated series that are now called HLA-A 
and HLA-B. The demonstration of crossover of the A and B 
antigens established HLA as a closely linked supergene. After 
1964 use of the micro cytotoxicity test greatly facilitated the stan-
dardization of HLA typing and the search for HLA antigens. The 
method was adapted for donor-recipient crossmatching and sub-
sequently for the detection of pretransplant sensitization to HLA 
alloantigens. 
HLA matching has been a stringent requirement for bone 
marrow transplantation (Table 2). For organ transplantation, the 
lymphocytotoxic crossmatch has been of crucial importance. Al-
though there is clear evidence that the HLA system contains the 
dominant histocompatibility antigens, it has not been possible to 
identify which mismatches would result in failure. Nonetheless, 
HLA-identical sibling kidney allografts provide the highest graft 
survival rates. These are approached by survival rates of zero 
HLA-mismatched cadaver kidneys, justifying kidney sharing. 
Quarter Century after 1974 
The advent of cyclosporine two decades ago was a watershed for 
both bone marrow [95J and organ [96] transplantation. When the 
new drug was substituted for azathioprine, allograft survival and 
the quality of recipient life improved dramatically. In particular, 
the transplantation of cadaver organs was upgraded from a fre-
quently feasible but unpredictable service to a reliable one. The 
results of organ transplantation were further enhanced after an-
other decade with the introduction of tacrolimus [97]. Other 
promising drugs and monoclonal antibody preparations have been 
introduced more recently or are in various stages of preclinical or 
clinical evaluation. However, the therapeutic principles have re-
mained essentially the same as were originally developed with 
azathioprine, prednisone, and ALG. 
With more potent immunosuppressive agents, the field of trans-
plantation has expanded continuously over the last 25 years. 
Heart-lung and lung transplantations were extensions of the heart 
procedure. Although survival of a lung recipient for 10 months 
had been accomplished as early as 1969 [98], the first examples of 
survival exceeding 1 year were not reported for heart-lung trans-
plantation until 1982 [99] and for lung transplantation until 1987 
[100]. Efforts at transplantation of abdominal organs expanded 
from the liver-only to the liver combined with small bowel [101] 
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Table 6. Tissue matching. 
Author 
Landsteiner 
Gorer 
Dausset 
Van Rood 
Payne 
Van Rood 
Starzl 
Terasaki 
Bach 
Bain 
Payne 
Van Rood 
Dausset 
Terasaki 
Kissmeyer·Nielsen 
Terasaki 
Van Rood 
Ceppellini 
Amos 
Kissmeyer·Nielsen 
Dausset 
Starzl 
Mickey 
Terasaki 
Van Leeuwen 
Discovery or application 
Discovery of ABO blood groups. 
Described single dominant histocompatibility locus (later H·2) 
in mouse, analogous to the human leukocyte antigen (HLA) 
system. 
Discovered first HLA antigen (MAC) using antiserum from 
transfused patients. 
Independently demonstrated HLA antibodies in pregnant 
women. 
First use of computers to make sense of the complex reactions 
produced by human antibodies, allowing identification of 
antigens currently known as HLA·B 4 and 6, as well as 
leukocyte antigen grouping. 
Hyperacute rejection of ABO·incompatible kidneys (from host 
isoagglutinins) and rules to prevent it. 
Description of microcytoxicity test, critical for further 
development and practical use of HLA typing, 
Independently described mixed lymphocyte culture (MLC) test 
of histocompatibility. 
Defined allelic system now known as HLA·A I, 2. and 3. 
Described antigens now known as HLA·B7+ B27 and HLA·B8 
as part of a closely associated system, 
Proposed single locus for the HLA system, analogous to the 
mouse H-2 system. 
Description of hyperacute kidney rejection associated with 
antigraft lymphocytotoxic antibodies and proposed 
prevention with cytotoxic crossmatch (Terasaki), confirmed 
and extended the following year with the leukoagglutinin 
test (Kissmeyer·Nielsen). 
First prospective trial of HLA matching for donor selection. 
Proposal that initiated the first international organ exchange 
orgamzation, 
Coined the term "haplotype" to indicate the chromosomal 
combination of HLA alleles. 
Showed that the MLC reaction was detecting the HLA·D 
locus. 
Described the first crossover between HLA-A and HLA·B, 
proving that HLA identified a chromosomal region and not 
a single locus, 
Demonstrated the importance of HLA compatibility for the 
survival of skin grafts in unmodified human volunteers. 
Long survival frequently achieved at all levels of HLA 
mismatch using a living donor and cadaveric kidneys. 
However, the best function, histologic appearance of 
allografts, and survival as welJ as the least dependence on 
immunosuppression was with zero·HLA mismatched kidney 
allografts. 
Identification of presensitized patients at high immunologic 
risk using the panel reactive antibody (PRA test). 
Identified the first sera that could be used for HLA·DR 
typing. This formed the basis on which HLA-DR serology 
was developed, 
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Year Reference 
1901 70 
1948 71 
1958 72 
1958 73 
1958 74 
1963 75 
1964 76 
1964 77 
1964 78 
1964 79 
1964 80 
1965 81 
1965 82 
1965 83 
1966 84 
1966 85 
1967 86 
1967 87 
1968 88 
1969 89 
1970 90 
1970-1 91 
92 
1971 93 
1973 94 
and to the more complex multiple abdominal visceral grafts [102]; 
in the end it resulted in successful engraftment of the small bowel 
alone [103], Tacrolimus played a crucial role in making the abo 
dominal procedures involving intestine clinically applicable. 
Success with this procedure still is achieved only in occasional 
cases. 
Although pancreas transplantation was offered at first only to 
diabetic patients who also were undergoing kidney transplantation 
for diabetes-associated end-stage renal disease [104], pancreas 
transplantation alone has been performed more recently in non· 
uremic diabetics [105]. The alternative appealing approach of 
transplanting the isolated islets of Langerhans only was attempted 
during the 1970s but did not result in success (defined as insulin 
independence) until 1990 in a patient with postpancreatectomy 
diabetes [106] and 1991 in a patient with type I diabetes (107]. 
Resume 
La transplantation d'organes, de cellules et de tissus a 
litteralement explosee dans ce dernier quart de sieele, avec Ie 
developpement d'une multitude de nouvelle specialites. 
Cependant, les principes de base qui ont rendu ceci possible ont 
ete etabli sur trois decennies, commen<;ant pendant la deuxieme 
guerre mondiale et terminant en 1974. Pendant la conference de 
consensus historique tenu it I'UCLA du 25 au 27 mars, 1999, 11 
chercheurs sur la transplantation travaillant en sciences 
----------------------
Groth et al.: Consensus Conference 
fondamentales et/ou en clinique se sont mis d'accord sur les 
contributions les plus significatives de cette periode et ont donne 
ii la discipline de transplantation sa credibilite presente. Ces 
decouvertes et accomplissements ont ete resumes en six tableaux, 
dotees de 93 references. 
Resumen 
En los ultimos 25 aoos se ha producido un autentico renacimiento 
por 10 que a trasplantes de organos, celulas y tejidos se refiere, 10 
que ha propiciado el desarrollo de multiples areas nuevas de 
especializacion. Sin embargo, los principios que hicieron posible 
los trasplantes se establecieron hace mas de 3 decadas, ya que las 
investigaciones al respecto se realizaron en el periodo de tiempo 
comprendido desde los comienzos de la 28 Guerra Mundial al 
final de 1974. En la historica conferencia de consenso, celebrada 
en UCLA, del 25 al 27 de marzo de 1999, 11 investigadores 
pioneros, procedentes tanto de las ciencias basicas como de la 
clinica y del tratamiento mediante trasplantes, alcanzaron un 
acuerdo sobre, cu3.les fueron los hitos mas importantes de este 
periodo, que permitieron que la tecnica de los trasplantes sea hoy 
una especialidad clinica bien definida y en continua expansion. 
Estos descubrimientos y realizaciones se resumen en 6 tablas y 93 
referencias bibliograficas. 
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